EGFR and colorectal cancer: The predictive role of BRAF mutation in colorectal cancer is currently debated, but a recent meta-analysis indicated that BRAF mutation is a predictive biomarker of poor prognosis in mCRC patients treated by anti-EGFR monoclonal antibodies, especially in KRAS wild-type patients [29].